天康生物(002100) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥3,339,230,680.67, representing a 68.35% increase compared to ¥1,983,537,035.47 in the same period last year[10] - The net profit attributable to shareholders for Q1 2021 was ¥301,009,811.74, a decrease of 10.03% from ¥334,552,715.62 in the previous year[10] - The basic earnings per share for Q1 2021 was ¥0.28, down 9.68% from ¥0.31 in the previous year[10] - Total revenue for Q1 2021 reached ¥3,339,230,680.67, a 68.35% increase compared to ¥1,983,537,035.47 in Q1 2020[26] - The company reported a net profit of ¥3,752,507,965.00 in retained earnings, an increase from ¥3,451,498,153.26[87] - The company reported a basic earnings per share of CNY 0.28, down from CNY 0.31 in the previous period[104] - Total comprehensive income for the current period is CNY 312,204,675.61, compared to CNY 325,628,705.24 in the previous period[105] Cash Flow - The net cash flow from operating activities increased by 14.57% to ¥585,028,585.93, compared to ¥510,611,919.66 in the same period last year[10] - Cash inflow from sales of goods and services reached ¥3,460,169,194.57, compared to ¥1,948,361,985.47 in the previous period, reflecting a significant increase of about 77.4%[113] - The net cash flow from operating activities was ¥585,028,585.93, up from ¥510,611,919.66 in the previous period, indicating a growth of approximately 14.5%[117] - The cash outflow for operating activities totaled ¥2,939,327,673.64, which is an increase from ¥1,578,966,528.20 in the previous period[117] - The net cash flow from financing activities was -¥583,151,019.49, worsening from -¥208,493,509.37 in the previous period[120] - The cash and cash equivalents at the end of the period were ¥1,732,129,657.41, down from ¥2,140,851,075.19 in the previous period, a decrease of approximately 19.0%[120] Assets and Liabilities - The total assets at the end of the reporting period were ¥15,942,521,786.11, a 1.36% increase from ¥15,729,293,585.91 at the end of the previous year[10] - The company's total current assets as of March 31, 2021, amounted to CNY 10.55 billion, a decrease from CNY 10.70 billion as of December 31, 2020[78] - The total liabilities decreased from CNY 4.76 billion to CNY 3.65 billion in the short-term borrowings category[81] - The company's fixed assets increased to CNY 3.87 billion from CNY 3.67 billion year-over-year[81] - The total assets of the company as of March 31, 2021, amounted to ¥8,034,771,704.95, up from ¥6,776,261,850.26 at the end of the previous year[94] - The total liabilities decreased to ¥3,770,170,582.67 from ¥3,004,931,418.58, indicating a reduction in financial obligations[94] - The company’s total current liabilities increased to ¥2,271,306,906.43 from ¥1,656,802,618.30, indicating a rise in short-term financial obligations[93] Investments and Financing - The company reported a total fundraising amount of RMB 1,000,000,000 from the issuance of 10 million convertible bonds, with a net amount of RMB 981,550,400 after deducting fees[63] - The company received ¥985,000,000.00 in borrowings during the current period, a significant increase from ¥20,000,000.00 in the previous period[120] - The company’s investment activities generated a cash outflow of ¥220,175,569.00, a 1065.11% increase, mainly due to larger investments in feed and breeding businesses[28] - The total cash outflow for investment activities was ¥220,175,569.00, compared to ¥97,475,700.00 in the previous period, indicating a substantial increase in investment expenditures[117] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 102,937[15] - The company’s equity attributable to shareholders increased to ¥4,264,601,122.28, compared to ¥3,771,330,431.68 in the previous year[94] - The company’s total equity increased to ¥7,214,422,701.14 from ¥6,867,687,523.05, reflecting a positive trend in shareholder value[87] Operational Costs and Expenses - Operating costs rose by 87.73% to ¥2,566,093,399.28, attributed to increased sales volume and cost recognition[26] - Sales expenses increased by 121.39% to ¥152,881,230.63, reflecting higher sales and transportation costs due to expanded sales activities[26] - The company reported a 161.50% increase in income tax expenses to ¥13,843,938.13, due to a higher tax rate for the newly established pharmaceutical company[26] - The company recorded a tax expense of CNY 13,843,938.13, up from CNY 5,294,011.26 in the previous period[102] Risk Management and Compliance - The company has implemented strict internal controls and risk management measures for its futures trading activities[42] - The company has not engaged in any entrusted financial management during the reporting period[70] - There were no violations regarding external guarantees during the reporting period[71] - The company has not reported any litigation related to its derivative investments[39]